Assessments REA (2016 – 2020)

Home  /  Assessments REA (2016 – 2020)
PROJECT IDPATIENT INVOLVEMENTTITLEPUBLICATION OF FINAL ASSESSMENTAUTHORCO-AUTHORSDEDICATED REVIEWERSPUBLICATION OF PROJECT PLAN
Pharmaceutical Technologies
PTJA09Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)TBDFIMEAAEMPS, AETSAHAS, AOTMiT, HVB, RER Observer: MoH UkraineTBD
PTJA08Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS)TBDINFARMEDNCPEAIFA, ZIN, SESCS/FUNCANIS,
RER
TBD
PTJA07Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy, a biologic, or have medical contraindications to such therapies TBDTLVAOTMiTUCSC Gemelli, NIPN, SNHTA,
SESCS/FUNCANIS Observer: NCPHA
TBD
PTJA06Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DBCL) TBDIQWIGHASFIMEA, SUKL, TLV, INFARMED
Observer: GBA
TBD
PTJA05Enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutationTBDNOMAAEMPS, AETSAHAS, AIFA, SNHTA, HIS, DPA/MOH MaltaTBD
PTJA04
Sotagliflozin for adult patients with Type 1 Diabetes Mellitus who have inadequate blood glucose control using insulin or insulin analogues

Patient Input - Diabetes Type 1
05.06.2019TLVZIN, NCPEAEMPS, SNHTA, NVD, INFARMED, AOTMiT
Observer: HIS, EOF
05.03.2019
PTJA03
Alecensa as monotherapy is indicated for the first-line treatment of adult patients with ALK+ advanced NSCLC23.01.2018TLVHVB, AAZNICE, Regione Veneto, AETSA, NIPN
Observer: MOH MALTA
20.10.2018
PTJA02Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib treatment25.10.2017HASINFARMEDAAZ, SNHTA, FIMEA, LBI-HTA, NIPN, AETSA
Observer: EOF, EKAPTY
10.07.2017
PTJA01
Midostaurin for the indication of Acute Myeloid Leukaemia08.11.2017FIMEANOMATLV, ZIN, HAS, NICE, AEMPS
Information retrieval: IQWIG
Observer: SUKL, EOPYY, SESCS
20.06.2017
Other Technologies
OTCA23Rectum spacers (i.e. spaceOAR) to reduce toxicity during radiotherapy for prostate cancerTBDNIPHNONSPHMPDBNICE, SNHTA, VASPVTTBD
OTCA22Clinical utility and diagnostic accuracy of Point-of-care Tests (POCT): D-Dimer and Troponin-TTBDLBI-HTANSPHMPDBSNHTA, HVBTBD
OTCA21Hypoglossal nerve stimulation systems for treatment of obstructive sleep apnoeaTBDAETS-ISCIIINSPHMPDBNIPHB, SFOPH/SNHTA, SESCSTBD
OTCA20Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR)02.07.2019AETS-ISCIIIMoH SloveniaUCSC Gemelli, SNHTA28.01.2019
OTCA19Screening for osteoporosis in the general population20.09.2019IQWiGSNHTAAQuAS, NSPHMPDB, GOG19.12.2018
OTCA18Regional hyperthermia for high-risk soft tissue sarcoma treatmentTBDNIPHNORERVASPVT, AETS-ISCIII, SNHTA14.05.2019
OTCA17Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH)TBDAGENASRERSNHTA, AETSA18.10.2018
OTCA16Bioresorbable Stents in cardiovascular indications (coronary artery disease)31.01.2019IAMEV/LBI-HTASNSMPSSESCS, HAS20.08.2018
OTCA15Irreversible electroporation in liver and pancreatic cancer21.06.2019AVALIA-TLBI-HTAVASPVT, NIPN, SNHTA23.10.2018
OTCA14Robotic surgery in thoracic and visceral indications 06.05.2019LBI-HTAReg. VenetoHIQA, DEFACTUM11.07.2018
OTCA13Vagal nerve blockade for obesityCancelled: expiration of CE approval for the technologyNIPHNOVASPVTSESCS/FUNCANIS, NIPHBCancelled: expiration of CE approval for the technology
OTCA12The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)29.01.2019HIQAHVBUCSC Gemelli, AETSA, AGENAS, HIS
Observer: AOTMiT
19.04.2018
OTCA11Custom-made or customisable 3D printed implants and cutting guides versus non-3D printed standard implants and cutting guides for improving outcome in patients undergoing knee, maxillofacial, or cranial surgery19.04.2019DEFACTUMOSTEBAGÖG, KCE, AAZ, NIPN16.11.2018
OTJA10Stool DNA testing for early detection of colorectal cancer26.07.2019GÖGNIJZ, JAZMPNICE, AGENAS, DEFACTUM, OSTEBA
Observer: MoH Slovenia
25.07.2018
OTCA09High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer12.04.2018LBI-HTAVASPVTSNHTA, AETS-ISCIII, OSTEBA26.02.2018
OTJA08
Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin27.07.2018AAZHVB, NIPHNOAQuAS, HIS, RER
Observer: ACSS-IP, AOTMiT
28.02.2018
OTCA07Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard ultrasound phacoemulsification cataract surgery26.10.2018RERGOG KCE, Osteba, SESCS/FUNCANIS and AQuAS
Observer: VASPVT
15.02.2018
OTCA06Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk21.12.2018AGENASNIPHNOSNHTA, OCSC, HIQA, KCE, REGIONE VENETO08.11.2017
OTCA05Repetitive transcranial magnetic stimulation for treatment-resistant major depression21.04.2017LBI-HTAOstebaKCE, FUNCANIS21.04.2017
OTCA04
Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer03.01.2018ZINKCELBI-HTA, HAS10.11.2017
OTCA03Screening of fetal aneuploidies whereby non-invasive prenatal test (NIPT)09.02.2018Avalia-tRERMIDT, SNHTA, NIPN, IQWIG
Observer: EOPYY
22.03.2017
OTCA02Antibacterial-coated sutures versus non-antibacterial-coated sutures for the prevention of abdominal, superficial and deep, surgical site infection (SSI)27.04.2017AAZNSPHMPDBSUKL, NIPN/OGYEI, VASPVT, SNHTA, IQWIG06.10.2016
OTCA01Wearable cardioverter-defibrillator (WCD) therapy
in primary and secondary prevention of sudden cardiac arrest in patients at risk
30.11.2016LBI-HTAAAZIQWIG, AVALIA-T18.08.2016

Bold means the assessment is ongoing. What does this  icon mean? Patients have been involved in this assessment.

General abbreviations: OT – other technologies; PT – pharmaceutical technologies; CA – collaborative assessment; JA – joint assessment

ASSESSMENT FAQs